Free leptin index and PAPP-A: a first trimester maternal serum screening test for pre-eclampsia

Area of Science:

• Obstetrics and Gynecology
• Maternal-Fetal Medicine
• Biomarker Discovery

Background:

• Pre-eclampsia (PE) is a significant pregnancy complication.
• Early detection of PE in the first trimester is crucial for timely intervention, such as low-dose aspirin prophylaxis.
• Maternal serum screening offers a non-invasive method for assessing PE risk.

Purpose of the Study:

• To evaluate the performance of first-trimester maternal serum screening for pre-eclampsia (PE).
• To assess the utility of free leptin index (fLI) and PAPP-A as biomarkers for PE detection.
• To determine if combining fLI and PAPP-A improves screening accuracy.

Main Methods:

• Analysis of first-trimester serum samples from 126 PE pregnancies and 289 controls.
• Calculation of gestational age and maternal weight-independent log MoM values for fLI and PAPP-A.
• Utilizing receiver-operator-characteristics curves to assess marker performance.
• Employing Monte Carlo simulation for estimating population screening performance.

Main Results:

• Free leptin index (fLI) was significantly elevated in PE pregnancies compared to controls (p < 0.001).
• PAPP-A levels were significantly reduced in PE pregnancies compared to controls (p < 0.001).
• Combined screening with fLI and PAPP-A demonstrated improved detection rates (22-35%) at various false positive rates (6-12%).

Conclusions:

• The combination of PAPP-A and fLI offers superior screening performance for pre-eclampsia compared to using either marker alone.
• This combined biomarker approach holds promise for enhancing early detection of PE.
• Improved screening can facilitate earlier prophylactic interventions, potentially reducing PE incidence and severity.